Amorfix and reMYND in A4 pact for AD
July 6, 2010 by leonardzehr · Leave a Comment
Amorfix Life Sciences (TSX:AMF) has signed a partnership agreement with reMYND NV of Belgium to offer the Amorfix A4 amyloid testing service to reMYND’s contract research clients. ”This partnership is an important first step to accessing new clients as we build our Alzheimer’s disease services business,” Vigen Nazarian, VP of strategic alliances for Amorfix, said [...]
Listen to BioTuesdays 
